GLAUKOS Corp

Public Equity (NYSE)Medical DevicesOphthalmologyPublic Company

📍 Aliso Viejo, CA, USA• Founded 1998

StreetZero Signal 68

Be the first to signal interest

About GLAUKOS Corp

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its flagship products include micro-invasive glaucoma surgery devices such as the iStent. The company is publicly traded on the NYSE under ticker GKOS and is based in Aliso Viejo, California.

LATEST FUNDINGRule 144

$10.6M

Announced 2026-10-30

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for GLAUKOS Corp.

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED1998

HQAliso Viejo, CA, USA

Industry

Public Equity (NYSE)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Glaukos pioneered micro-invasive glaucoma surgery (MIGS) with the iStent.
Publicly listed on NYSE under ticker GKOS.
Develops therapies for glaucoma, corneal disorders, and retinal diseases.
Headquartered in Aliso Viejo, California.

Ask StreetZero about GLAUKOS Corp

Put our AI to work on this deal.

What is GLAUKOS Corp's value proposition?Who are GLAUKOS Corp's competitors?Why does this raise matter?Summarize GLAUKOS Corp for an investor.

Similar companies

Other Public Equity (NYSE) deals, ranked by Signal.

Arista Networks, Inc.

$45.2M

Chubb Ltd

$16.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.